Geode Capital Management LLC Has $2.04 Million Stock Holdings in Gossamer Bio, Inc. (NASDAQ:GOSS)

Geode Capital Management LLC increased its holdings in shares of Gossamer Bio, Inc. (NASDAQ:GOSS) by 1.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,250,461 shares of the company’s stock after purchasing an additional 38,084 shares during the period. Geode Capital Management LLC owned approximately 0.99% of Gossamer Bio worth $2,037,000 at the end of the most recent quarter.

Separately, Charles Schwab Investment Management Inc. lifted its stake in Gossamer Bio by 1.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,241,979 shares of the company’s stock valued at $1,123,000 after purchasing an additional 13,902 shares during the last quarter. 81.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Gossamer Bio in a research report on Tuesday, March 18th. Wedbush reaffirmed an “outperform” rating and issued a $4.00 price objective on shares of Gossamer Bio in a research note on Friday, March 14th. Finally, The Goldman Sachs Group dropped their price target on Gossamer Bio from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Thursday, April 17th.

Gossamer Bio Price Performance

Shares of NASDAQ:GOSS opened at $0.88 on Wednesday. The company has a debt-to-equity ratio of 3.64, a quick ratio of 6.74 and a current ratio of 6.74. The company has a market capitalization of $200.34 million, a P/E ratio of -2.76 and a beta of 1.88. The company’s 50-day moving average is $1.08 and its 200 day moving average is $0.98. Gossamer Bio, Inc. has a fifty-two week low of $0.50 and a fifty-two week high of $1.55.

Gossamer Bio (NASDAQ:GOSS) last issued its earnings results on Tuesday, March 18th. The company reported ($0.15) EPS for the quarter, hitting the consensus estimate of ($0.15). The company had revenue of $9.38 million during the quarter, compared to the consensus estimate of $7.02 million. On average, equities research analysts forecast that Gossamer Bio, Inc. will post -0.28 earnings per share for the current year.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.